Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)

David Couper; Lisa M. LaVange; Mei Lan Han; R. Graham Barr; Eugene Bleecker; Eric A. Hoffman; Richard Kanner; Eric Kleerup; Fernando J. Martinez; Prescott G. Woodruff; Stephen Rennard

doi:10.1136/thoraxjnl-2013-203897

Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)

David Couper, Lisa M. LaVange, Mei Lan Han, R. Graham Barr, Eugene Bleecker, Eric A. Hoffman, Richard Kanner, Eric Kleerup, Fernando J. Martinez, Prescott G. Woodruff, Stephen Rennard

Research output: Contribution to journal › Article › peer-review

324 Scopus citations

Abstract

Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

Original language	English (US)
Pages (from-to)	491-494
Number of pages	4
Journal	Thorax
Volume	69
Issue number	5
DOIs	https://doi.org/10.1136/thoraxjnl-2013-203897
State	Published - May 2014
Externally published	Yes

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1136/thoraxjnl-2013-203897

Cite this

@article{329104b9180d4a10a83d72c8472c61f3,

title = "Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)",

abstract = "Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.",

author = "David Couper and LaVange, {Lisa M.} and Han, {Mei Lan} and Barr, {R. Graham} and Eugene Bleecker and Hoffman, {Eric A.} and Richard Kanner and Eric Kleerup and Martinez, {Fernando J.} and Woodruff, {Prescott G.} and Stephen Rennard",

year = "2014",

month = may,

doi = "10.1136/thoraxjnl-2013-203897",

language = "English (US)",

volume = "69",

pages = "491--494",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "5",

}

TY - JOUR

T1 - Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)

AU - Couper, David

AU - LaVange, Lisa M.

AU - Han, Mei Lan

AU - Barr, R. Graham

AU - Bleecker, Eugene

AU - Hoffman, Eric A.

AU - Kanner, Richard

AU - Kleerup, Eric

AU - Martinez, Fernando J.

AU - Woodruff, Prescott G.

AU - Rennard, Stephen

PY - 2014/5

Y1 - 2014/5

N2 - Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

AB - Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

UR - http://www.scopus.com/inward/record.url?scp=84898914338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898914338&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2013-203897

DO - 10.1136/thoraxjnl-2013-203897

M3 - Article

C2 - 24029743

AN - SCOPUS:84898914338

SN - 0040-6376

VL - 69

SP - 491

EP - 494

JO - Thorax

JF - Thorax

IS - 5

ER -

Design of the subpopulations and intermediate outcomes in copd study (SPIROMICS)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this